CareDx (NASDAQ:CDNA) Issues Earnings Results, Beats Expectations By $0.45 EPS

CareDx (NASDAQ:CDNA) issued its earnings results on Thursday. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45, FiscalAI reports. CareDx had a net margin of 24.23% and a return on equity of 2.87%.

Here are the key takeaways from CareDx’s conference call:

• Strong financial performance: Q3 revenue rose 39% year over year to $139 million, testing volume increased 51% to 75,900 tests, adjusted EBITDA doubled to $30 million, and the company ended the quarter with $250 million in cash and no debt. Management raised full-year 2026 revenue guidance to $520 million–$530 million and adjusted EBITDA guidance to $90 million–$100 million.
• The transplant franchise delivered 21% year-over-year volume growth, led by continued adoption in kidney and lung, while 21 centers are now live on Epic Aura. Management said it expects roughly half of transplant orders to flow through electronic medical-record integrations by year-end, supporting further workflow adoption.
• NavDx specialty oncology revenue grew 37% year over year on a comparable basis, and CareDx is expanding its commercial team, patient access services, electronic ordering, and billing infrastructure. Management believes NavDx revenue per test can increase from approximately $823 to $1,000 or more over time as evidence and adoption expand.
• CareDx remains on track to launch AlloHeme for AML and MDS recurrence monitoring in Q1 2027 and broaden HistoMap Kidney availability in 2027. However, management indicated that meaningful AlloHeme revenue is likely to emerge in 2029, with coverage potentially materializing in 2028, while NavDx radiation-de-escalation evidence remains based primarily on early phase II studies.

CareDx Stock Performance

Shares of NASDAQ:CDNA traded down $0.61 during mid-day trading on Thursday, hitting $71.52. The stock had a trading volume of 1,672,127 shares, compared to its average volume of 954,161. The company’s 50 day moving average is $58.62 and its 200-day moving average is $33.03. CareDx has a 12-month low of $14.23 and a 12-month high of $73.43. The company has a market cap of $3.70 billion, a PE ratio of 34.55 and a beta of 2.38.

Insider Activity at CareDx

In other CareDx news, Director George Bickerstaff, III sold 20,000 shares of CareDx stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $46.28, for a total transaction of $925,600.00. Following the transaction, the director directly owned 134,061 shares in the company, valued at approximately $6,204,343.08. The trade was a 12.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christine Cournoyer sold 16,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $46.94, for a total transaction of $751,040.00. Following the sale, the director directly owned 42,943 shares in the company, valued at approximately $2,015,744.42. This trade represents a 27.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

CDNA has been the subject of a number of recent research reports. HC Wainwright reiterated a “neutral” rating and set a $46.00 price objective on shares of CareDx in a research report on Friday, July 31st. Zacks Research lowered CareDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. William Blair raised CareDx to a “hold” rating in a research report on Thursday, July 16th. Canaccord Genuity Group upped their target price on CareDx from $65.00 to $80.00 and gave the company a “buy” rating in a report on Monday, October 19th. Finally, BTIG Research increased their price target on CareDx from $74.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, CareDx currently has a consensus rating of “Hold” and a consensus target price of $58.40.

CareDx Company Profile

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.